High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
The San Diego company is trying to carve out a place beside Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy with a dual GLP-1/GIP drug that can be given as a shot or, later, a pill.
Viking Therapeutics surged more than 26% on fresh GLP-1 maintenance data while every major obesity peer from Eli Lilly to Novo Nordisk barely registered a pulse, raising a pointed question about whether this catalyst belongs to Viking alone or signals something bigger.
Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly.
Viking Therapeutics’ experimental obesity drug showed it could preserve most patients’ prior weight loss with less frequent dosing.
Semaglutide will start losing patent protection in the near future.
Chair and CEO Dave Ricks told CNBC that about one-third of new patients starting a GLP-1 tablet are now on Foundayo, and that Lilly’s share of that oral market is still rising week by week.
CagriSema beat 5-milligram tirzepatide in diabetes--not Lilly's full dosing range or broader obesity franchise.
Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.
The Committee for Medicinal Products for Human Use recommended European Union marketing authorization for Frehemgo in adults and children with haemophilia A on Thursday.
LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.
These stocks have been struggling lately, but they could be underrated buys in the long run.
Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Ascendis Pharma (ASND) will regain exclusive rights to certain drug treatments for metabolic and car
The approval extends semaglutide beyond obesity, but Novo disclosed neither launch timing nor incremental revenue.
AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
Eli Lilly just crossed the trillion-dollar threshold on the back of a GLP-1 empire growing at nearly 50% annually, but a recent pullback and rising risks are forcing investors to decide whether this pharmaceutical giant still has meaningful upside left.
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
You might regret ignoring these companies at current levels.
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.
They are way more than just GLP-1 stocks.
WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
